Zealand Pharma stock get Buy from BTIG on obesity pipeline promise
Investing.com | Editor Emilio Ghigini
Published Mar 07, 2024 04:07AM ET
On Thursday, Zealand Pharma A/S (NASDAQ:ZEAL) stock received a Buy rating from BTIG, reflecting optimism about the company's potential in the obesity treatment market. The firm's analyst highlighted Zealand's year-to-date performance, which has significantly outstripped the broader biotech sector, and anticipates further growth driven by forthcoming clinical data.
Zealand's stock has seen a notable increase, rising 78.3% compared to the 12.1% gain of the XBI biotech index. The company's obesity pipeline, which includes a range of incretins and an amylin analog named petrelintide, is considered to have best-in-class features. Petrelintide, in particular, is expected to become a next-generation treatment option.
Clinical data for petrelintide is expected in the first half of 2024, with a 16-week study involving 48 participants. This data event is seen as a potential turning point for Zealand's shares. The treatment is anticipated to be well-received due to its ability to preserve lean body mass and cause fewer gastrointestinal side effects compared to the standard of care.
Additionally, the company has two near-commercial rare disease therapies with little competition, which are expected to be highly successful and potentially reach $1.9 billion in combined peak sales. Zealand's partnership with Boehringer Ingelheim on a GLP-1/GCG agonist is also seen as a strong player in the obesity market with payor support.
The company's other drug, glepaglutide, is positioned to challenge Gattex, with a current run-rate of over $800 million, for the treatment of short bowel syndrome (SBS). The lack of impressive Phase 3 data from competitors last month further strengthens Zealand's position in this rare disease market.
Lastly, the manufacturing-related Complete Response Letter (CRL) for Zealand's congenital hyperinsulinism (CHI) program dasiglucagon is expected to be resolved with a New Drug Application (NDA) resubmission later in the first half of 2024. This adds to the company's portfolio of rare disease treatments facing minimal competition.
The positive outlook from BTIG is capped with a price target of DKK 840 for Zealand Pharma, setting a high expectation for the company's growth and success in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Get The News You Want
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.